Correction to: Leukemia https://doi.org/10.1038/s41375-020-0743-y, published online 14 February 2020
In this article, Figure 1 was incorrect.
The updated figure can be found below.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Lenz, G., Hawkes, E., Verhoef, G. et al. Correction: Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia 38, 469–472 (2024). https://doi.org/10.1038/s41375-023-02133-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-023-02133-2
